Novartis signs $8B drug licensing deal with Abogen Biosciences
by@axios
Summary
Novartis has entered into a significant drug licensing agreement with China's Abogen Biosciences, potentially worth up to $7.8 billion. This deal, which includes an upfront payment of $575 million for an mRNA-encoded T-cell engager aimed at treating autoimmune diseases, reflects a growing trend of Western pharmaceutical companies partnering with Chinese biotech firms to access innovative therapies. As China shifts from being primarily a supplier of pharmaceutical ingredients and generics to developing advanced new drugs with government backing, this collaboration may signal the country's aspiration to rival the United States in the pharmaceutical landscape.
Tokens
$NVS
Analysis
Novartis: Novartis is a global pharmaceutical company focused on developing and commercializing innovative medicines across therapeutic areas including oncology, immunology, and neuroscience. In this news, the company entered a licensing agreement with Abogen Biosciences for an mRNA-based therapy targeting autoimmune diseases. Caitlin Owens: Caitlin Owens is a health policy reporter at Axios covering pharmaceutical and biotech industry developments. She provided the bottom-line analysis in the article, highlighting China's progress in new drug creation. Abogen Biosciences: Abogen Biosciences is a Chinese biotechnology company specializing in mRNA technology and therapeutic development. It is directly involved in the reported licensing deal, granting Novartis rights to an mRNA-encoded T-cell engager under development. Partnership Trend: Western pharmaceutical companies continue to form major licensing deals with Chinese biotech firms to access advanced therapies. China's Drug Development Shift: China is transitioning from a supplier of pharmaceutical ingredients and generics toward becoming a developer of innovative new drugs with government support.
Categories
macropolitics